GEN

 
TIDMGEN 
 

Media Release

   -- Event to be held live in New Orleans, Louisiana 
 
   -- Meeting to be webcast live and archived on www.genmab.com 

Copenhagen, Denmark; December 12, 2022 -- https://www.globenewswire.com/Tracker?data=O5t7wi3CeS9YFwqF8ChOVABZzcvqSTVHzjr9ektRAfZU4G2gzPUUPbdbedR4fPGOuK-tk7HX55Q3hOC_ociOUQ== Genmab A/S (Nasdaq: GMAB) will hold its 2022 R&D Update and ASH Data Review Meeting today, December 12, 2022 at 8:00 PM Eastern Time (7:00 PM CST / 1:00 AM GMT on December 13). The event will take place live at the Four Seasons New Orleans in New Orleans, Louisiana, Plimsole Ballroom B. Those wishing to attend in person may register on site.

The event can also be attended via webcast. To register for the webcast, click here https://www.globenewswire.com/Tracker?data=waT38C8d8uGAniGVoqxeYICO6Cxzfd47rk40B-kru4WztA-AUNXQcAVlV8HxZ_N-9HA-KOJVTHyWqzTyWJCeX0p1pb_jAPKOATsd2MFEzR7ZIsnQWI8AK64bWDy5PEg0wAeB1Go_IaClxKnQ9IJ6jM7I6zJaJUI2yu9GXyRXQcI= . Webcast viewers may submit questions during the Q&A portion of the live webcast via the webcast player. An archive of the webcast will be available on Genmab's website. The webcast will be conducted in English.

This meeting is not an official program of the ASH Annual Meeting.

About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab's vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people's lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab's proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com https://www.globenewswire.com/Tracker?data=O5t7wi3CeS9YFwqF8ChOVPyREiGmL0DPQoAIrtTXMEYsKcAqja8olYXm8kt613TRFhhFjVcoloFLGvm0SGmrOA== and follow us on Twitter.com/Genmab https://www.globenewswire.com/Tracker?data=MMGE_B1PpIyB4GHqAROPsi9XqBgoyu9uGzDCJgbtDS7DgH_AVGVmBkXG8hKf9QPRl4L2UoH74WmiajaoHVT8htRL2JQPqdjiwP---XS1-eI= .

Contact:

Marisol Peron, Senior Vice President, Communications and Corporate Affairs

T: +1 609 524 0065; E: mmp@genmab.com https://www.globenewswire.com/Tracker?data=-x1Y29E2b5vnPpwUF_kbum1O_Q3CnBNOoDhZ08OYsuwHFjHiDyU2KH5GgGbqI6D3K1s73Q8IBYgtAVkxdMS6Wg==

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com https://www.globenewswire.com/Tracker?data=jIvnilslGyP7RZnzoChLx0O8z1s_8FfTO1qIJvAoXf2_B26nM6ZBbiJYuaap39iLBIFAoi75vhtNJ-XDSn66DQ==

This Media Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on https://www.globenewswire.com/Tracker?data=4i3F4CiURwlNoKfqprPRnyvSIew4GV0qunKt8vrUBwtouaaTZ7SymmmxGWkoWvram4SoEFWbHm_pkPaDRhtnCQ== www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at https://www.globenewswire.com/Tracker?data=4i3F4CiURwlNoKfqprPRn7eqtez9d1bYAhfBL6I4Z6FHyJXXMBQQ-IpYWfpdzwnhl4ORJ0a5psveZ6ZVJIqxFxQDBLJO8W603IJIPg85WSE= www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in combination with the HexaBody logo(R) ; DuoHexaBody(R) and HexElect(R) .

Media Release no. 19

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

   -- i19_121222_Post ASH Event 
      https://ml-eu.globenewswire.com/Resource/Download/296eb4e5-4954-4020-b47a-17c616009dde 
 
 
 

(END) Dow Jones Newswires

December 12, 2022 08:23 ET (13:23 GMT)

Genuit (LSE:GEN)
Historical Stock Chart
From Feb 2023 to Mar 2023

Genuit (LSE:GEN)
Historical Stock Chart
From Mar 2022 to Mar 2023